ZR2 Sequential Immunochemotherapy for Newly Treated MCL

Clinical trial NCT05992597 · RECRUITING

Trial details

NCT number: NCT05992597
Sponsor: Zhejiang Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma

Start date: 2022-08-01
Primary completion: 2025-08-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.